Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

por Gennari, A, Bruzzi, P, Orlandini, C, Salvadori, B, Donati, S, Landucci, E, Guarneri, V, Rondini, M, Ricci, S, Conte, P
Publicado 2004

1725P Development and validation of telematic follow-up for cancer patients during the COVID-19 outbreak

por Pastorino, A., Negru, M.E., Vigani, A., Vaira, F., Tognoni, A., Ferrari, A., Ricci, I., Rondini, M., Olcese, F., Milano, A., Cozzani, F., Aschele, C.
Publicado 2020

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

por Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Publicado 2005